Stock 002940 ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 03/06/2024 BST 		5-day change 1st Jan Change
16.78 CNY -2.16% Intraday chart for Zhejiang AngLiKang Pharmaceutical CO.,LTD. -6.78% -22.71%
04-26 Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-02 Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug
MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets
MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates
MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China
MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China
MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022
CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm
MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List
MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002940 Stock
  4. News Zhejiang AngLiKang Pharmaceutical CO.,LTD.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW